BioRestorative Therapies (FRA:9OF) Retained Earnings : €-137.01 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BioRestorative Therapies's retained earnings for the quarter that ended in Mar. 2024 was €-137.01 Mil.

BioRestorative Therapies's quarterly retained earnings increased from Sep. 2023 (€-153.88 Mil) to Dec. 2023 (€-134.52 Mil) but then declined from Dec. 2023 (€-134.52 Mil) to Mar. 2024 (€-137.01 Mil).

BioRestorative Therapies's annual retained earnings declined from Dec. 2021 (€-118.72 Mil) to Dec. 2022 (€-128.65 Mil) and declined from Dec. 2022 (€-128.65 Mil) to Dec. 2023 (€-134.52 Mil).

BioRestorative Therapies Retained Earnings Historical Data

The historical data trend for BioRestorative Therapies's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Retained Earnings Chart

BioRestorative Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-70.71

-73.85

-118.72

-128.65

-134.52

BioRestorative Therapies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-147.88	-148.89	-153.88	-134.52	-137.01

BioRestorative Therapies Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

BioRestorative Therapies (FRA:9OF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

BioRestorative Therapies (FRA:9OF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

BRTX:USA 9OF:Germany

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies (FRA:9OF) Headlines

No Headlines